Valuing COVID-19 Mortality and Morbidity Risks
2021
In this report, the researchers develop an approach for valuing COVID-19 mortality and morbidity risk reductions that builds on the U.S. Department of Health and Human Services (HHS) Guidelines for Regulatory Impact Analysis. They review the differences between COVID-19 mortality risks and the types of risks that are more commonly studied, and find that the impacts of these differences on the value of mortality risk reductions (the value per statistical life, VSL) are uncertain. They then develop estimates of the value of COVID-19 morbidity risk reductions, based on estimates of the effects of similar diseases on health-related quality of life. The report includes illustrative estimates that can be used to value the benefits of averting nonfatal cases of COVID-19.
Valuing COVID-19 Mortality and Morbidity Risks
Source:
Robinson LA, Eber MR, Hammitt JK. Valuing COVID-19 Mortality and Morbidity Risk Reductions in U.S. Department of Health and Human Services Regulatory Impact Analyses. Office of the Assistant Secretary for Planning and Evaluation (ASPE), U.S. Department of Health and Human Services 2021. https://aspe.hhs.gov/reports/valuing-covid-19-risk-reductions-hhs-rias